Immunovia AB (publ)
IMMVF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.01 | -0.62 | -13.28 |
| FCF Yield | -143.41% | -222.28% | -22.17% | -10.84% |
| EV / EBITDA | -0.70 | 0.04 | -5.16 | -10.16 |
| Quality | ||||
| ROIC | -606.59% | -415.93% | -67.93% | -35.67% |
| Gross Margin | 100.00% | -324.25% | -267.77% | 1,873.58% |
| Cash Conversion Ratio | 0.88 | 0.48 | 0.92 | 0.92 |
| Growth | ||||
| Revenue 3-Year CAGR | -6.66% | 23.12% | 46.79% | 33.34% |
| Free Cash Flow Growth | 34.68% | 16.41% | -0.21% | -5.13% |
| Safety | ||||
| Net Debt / EBITDA | 0.40 | 0.49 | 0.48 | 1.88 |
| Interest Coverage | -58.82 | -254.25 | -119.47 | -116.36 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 2.09 | -6.96 |
| Cash Conversion Cycle | 1,284.36 | -429.27 | 149.11 | 235.86 |